At the end of August, the Hunan Provincial Medical Insurance Bureau issued a notice on the implementation of the centralized procurement of the inter-provincial alliance of proprietary Chinese medicines, which showed that the results of the selection of the centralized procurement of the inter-provincial alliance of proprietary Chinese medicines were implemented
on October 20, 2022 on the province's unified medical insurance information platform "Drug and Medical Consumables Recruitment management subsystem".
At the same time, all drugs in the same product group stopped being purchased on the centralized procurement platform of the original provincial medicine
.
This also means that in more than a month, a batch of proprietary Chinese medicines in Hunan Province will reduce prices
.
Judging from the selected varieties collected by the Interprovincial Alliance of Proprietary Chinese Medicines in Hunan Province, a total of 17 procurement groups are involved, including 279 quality drugs
such as Danshen injection, blood-activating analgesic capsules, kidney failure Ning tablets, Shu hexining injection, Shuanghuanglian oral liquid, and hemoset.
From the perspective of the selected price, many varieties of a single piece are reduced to less than 1 yuan, such as the 2ml specification of Shenghe Pharmaceutical's Ginseng Mai Injection, the selected price is 0.
77 yuan / stick, and the Hessetong Injection of Kangyuan Pharmaceutical and Yunnan Plant Pharmaceutical is 2ml: 100mg specification, and the selected price is also within 1 yuan, which is 0.
66 yuan / stick and 0.
78 yuan / bottle
, respectively.
The notice makes it clear that the centralized procurement cycle of proprietary Chinese medicines is in principle 2 years, calculated
from the date of implementation of the selection results.
During the procurement cycle, a purchase and sale agreement
is signed every year.
Each medical institution should complete the purchase volume of the agreement within the procurement cycle, and the part exceeding the purchase amount of the agreement, the selected enterprise still needs to supply according to the selected price until the expiration
of the procurement cycle.
At the same time, it is required to do a good job in maintaining basic information, ensuring the quality supply of drugs, signing a purchase and sale agreement with quantity, standardizing the purchase and use behavior, trial direct settlement of payment, and promoting the task of
price coordination on the hanging network.
In terms of basic information maintenance, the selected drugs are directly hung on the medical insurance recruitment system according to the selected price, and are included in the "Selected Catalogue of Proprietary Chinese Medicines" management
.
In order to encourage fair competition and further give play to the role of the drug market price formation mechanism with quantity procurement, if the average daily treatment cost of non-selected drugs in the same product group is lower than the minimum daily average treatment cost of the selected drugs in the same product group, it may be included in the selected catalogue
upon application.
In terms of procurement and use, it is clear that medical institutions should smooth the channels
for selected drugs to enter the hospital.
In addition to the amount of procurement agreed, medical institutions may purchase unselected drugs with appropriate prices according to clinical needs, and the purchase amount of all drugs (including selected drugs and non-selected drugs) in the collection catalogue of proprietary Chinese medicines shall not exceed 85%
of the same period of the previous year.
In addition, in order to ensure the stable supply of the selected varieties and ensure the safety of patient use, the notice clarifies that the medical insurance agencies at all levels should include the implementation of the procurement work of medical institutions in the annual assessment indicators of the fixed-point agreement management, and the medical institutions that have seriously lagged behind in the progress of the work, the number of procurement, and the amount of procurement are obviously abnormal, and measures such as interviews, letters, suspension of refusal to pay medical insurance settlement funds, and corresponding deductions of the annual medical insurance reservation will be punished
according to the situation.
If the selected enterprises cannot guarantee the quality and quantity of the selected varieties, they will be subject to compensation, punishment, withdrawal, alternative and emergency safeguard measures, and the pharmaceutical enterprises that cannot perform the contract well will be recorded, substantively included in the enterprise's supply capacity and performance evaluation, and will be dealt with accordingly according to the discretionary benchmarks of pharmaceutical prices and credit evaluation of recruitment, depending
on the severity of the circumstances.
